-
Dean Charney Lures PacBio’s Schadt to Mount Sinai
Bio-IT World | Dennis Charney, Dean of the Mount Sinai School of Medicine (MSSM), says he went after Pacific Biosciences CSO Eric Schadt "big time" to head MSSM’s new Institute of Genomics and Multiscale Biology and the Department of Genetics.
May 16, 2011
-
PacBio CSO Eric Schadt to Lead ‘Multiscale Institute’ at Mount Sinai
Bio-IT World | Pacific Biosciences has announced a bi-coastal partnership with Mt Sinai School of Medicine (MSSM) in New York City to create the Institute for Genomics and Multiscale Biology. The new institute will be lead by PacBio’s chief science officer Eric Schadt, who will nonetheless retain his position at PacBio.
-
The Newest of the Next Generation Sequencers
Technology Review | The newest sequencing company, Noblegen, is developing a "simplified version" of nanopore sequencing, says the company, that will be able to sequence a genome every 30 seconds.
May 15, 2011
-
Broad Institute, IBM, Among EMC’s Inaugural ‘Data Heroes’
Bio-IT World | The IT group at the Broad Institute and the IBM team that developed the Watson supercomputer, are among the winners of EMC’s inaugural Data Hero Awards, announced this week at EMC World in Las Vegas.
May 11, 2011
-
Battelle Report Finds $800-Million Economic Impact of Human Genome Project
Fast Company | The Human Genome Project has driven $796 billion in economic impact and generated $244 billion in total personal income, according to a new report from Battelle.
May 11, 2011
-
More Big Biotech Mergers On the Way
Reuters | Major drugmakers need the growth potential of biotech now more than ever, says David Snow, even though drug executives and bankers are keeping quiet on big price tag mergers and acquisitions.
May 10, 2011
-
DNA2.0 Offers Third-Party Genetic Constructs
Bio-IT World | DNA2.0 will announced that it will offer third-party genetic constructs through the company’s groundbreaking gene assembly and design application, Gene Designer, tomorrow at PEGS 2011 in Boston.
May 9, 2011
-
Illumina Announces $5,000 Genome Pricing
Bio-IT World | Illumina is lowering the price for sequencing whole human genomes through its the Illumina Genome Network (IGN) to $5,000 per genome (for orders of ten samples or more) and just $4,000 for projects of 50 samples or more.
May 9, 2011
-
PacBio Shares Fall
Motley Fool | PacBio shares fell 12% yesterday after commentary plugged Illumina and Life Technologies and hinted that GE and IBM may enter the market.
May 3, 2011
-
BGI Shenzhen is World's Largest Sequencing Facility
Newsweek | The world's largest genome sequencing facility is in Shenzhen, China. 128 Illumina HiSeq 2000s are in the Shenzhen BGI facility, a modest building in a gritty neighborhood surrounded by mechanics and scrap yards.
May 1, 2011
-
Get SMRT: Pacific Biosciences Unveils Software Suite with Commercial Launch
Bio-IT World | Pacific Biosciences marks the long-awaited commercial shipment of its single-molecule DNA sequencer this week with a package of custom software tools. The SMRT (single molecule/real time) Analysis software suite features web-based tools and algorithms for sequence alignment and de novo assembly, and even offers information on the kinetics of nucleotide incorporation.
Apr 29, 2011
-
Myriad Genetics Buys Rules-Based Medicine
Statesman | Myriad Genetics has agreed to buy Rules-Based Medicine for $80 million in cash.
Apr 28, 2011
-
Oxford Nanopore Raises Another $41 Million for GridION Platform
Bio-IT World | Oxford Nanopore Technologies has raised a further £25 million ($41 million) in new private funding round that will support further development for the British firm's molecular sensing and next-generation sequencing technology.
-
PatientsLikeMe Study Shows Social Media's Value as Research Tool
Wall Street Journal | A new clinical trial using social networking, conducted by researchers at Patients Like Me and published in Nature Biotechnology, shows the potential value of recruiting and analyzing data from volunteers in a virtual trial at a fraction of the cost and time of traditional trials, even as it refutes the claims of previously published trial on the effects of lithium in patients with Lou Gehrig's disease.
Apr 25, 2011
-
Meet Tanuki, a 10,000-core Supercomputer in the Cloud
Bio-IT World | Connecticut-based Cycle Computing recently helped Genentech successfully spin up a 10,000-core supercomputer named Tanuki in the Amazon cloud, and CEO Jason Stowe sees no reason why he can't go further still.
Apr 25, 2011
-
Oracle Software Supporting Moffitt’s Personalized Medicine Ambitions
Bio-IT World | Moffitt Cancer Center recently announced that it selected Oracle Health Sciences solutions as the foundation for its next-generation health and research informatics platform. The groundbreaking partnership will support efforts by Moffitt’s longitudinal research initiative Total Cancer Care (TCC) to supply doctors of the future with a bedside decision-making tool for better matching patients to trials and treatments, says Mark Hulse, R.N., vice president, information technology and chief information officer at Moffitt Cancer Center.
Apr 20, 2011
-
Hey, Where Did the Cloud Go?
The Atlantic Wire | An outage at Amazon's cloud-based EC2 (Elastic Compute Cloud) Web hosting service, reportedly affecting servers in Virginia, took down a number of popular social media sites, including Foursquare, Reddit, and Hootsuite.
Apr 21, 2011
-
Genome Sequencing in Clinic Leads to Life-Saving Cancer Treatment
AFP | In another example of sequencing in the clinic, researchers at Washington University's Genome Institute have used a patient's genome to inform clinical decisions about leukemia treatment.
Apr 21, 2011
-
The Value of Outsourcing Bioinformatics
Guest Commentary | With reducing R&D budgets, revenue streams under threat from expiring drug patents, and general loss of consumer confidence, every biotech organization is faced with making difficult decisions about the future structure and purpose of R&D teams. Outsourcing is vital to the ongoing ability of bioinformatics teams to effectively support R&D activities within their organizations.
Apr 20, 2011
-
Blueprint Medicines Target Cancer with Genomics
Technology Review | Blueprint Medicines, which announced $40 million in funding from Third Rock Ventures, is planning to develop drugs designed to target cancer cells with genomics.
Apr 19, 2011